EUVIMEDEUVIMED entdecken
Crossref

A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy

Filip K. Knop, Shweta Urva, Mallikarjuna Rettiganti, Charles T. Benson, William C. Roell, Kieren J. Mather, Axel Haupt, Edward Pratt, Martin Füchtenbusch

Diabetologie und Stoffwechsel · 01.04.2024 · 19 (S 01 S 01) · S73

DOI: 10.1055/s-0044-1785380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetologie und Stoffwechsel, erschienen am 01.04.2024. Verfasst von Filip K. Knop und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

How does LY3537021 (LY) in combination with liraglutide impact the safety and tolerability profile related to gastrointestinal (GI) adverse events?

Methods

In a phase 1, double-blinded, randomized, crossover study, participants were assigned to pre-treatment with a single subcutaneous dose of LY versus placebo, followed by 8 days of treatment with escalating doses of liraglutide from 0.6 to 2.4 mg intended to elicit GLP-1-related GI symptoms. The frequency of GI-related adverse events was measured. There was an 8-week washout between treatment phases.

Results

Thirty-two healthy participants were dosed and 31 completed both periods of the trial. All 32 patients were included for analyses of safety data. Compared with the liraglutide+placebo phase of the trial, the total number of GI adverse events in the liraglutide+LY phase was reduced (73 versus 41; p=0.02), with fewer mean events per participant (2.28 versus 1.28). During the liraglutide+LY phase, a smaller proportion of participants experienced GI adverse events compared to the liraglutide+placebo phase (53% versus 72%; p=0.13). While on LY, the proportion of participants affected by three of the most common GLP-1-related GI events (nausea, vomiting, and gastro-esophogeal reflux) decreased by approximately 20-65% versus placebo (total of 13 on LY versus 26 on placebo). LY also reduced the total number of common liraglutide-associated GI events (nausea, vomiting, and gastro-esophogeal reflux) by approximately 45-65% (20 on LY versus 41 on placebo).

Conclusion

These results suggest that long-acting GIP receptor agonism may enable improvement in tolerability to the GI adverse events associated with GLP-1 receptor agonist therapy, which may contribute to the improved clinical benefits noted with long-acting GIP/GLP-1 receptor co-agonism. Publication History Article published online: 18 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., Pratt, E., & Füchtenbusch, M. (2024). A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy. Diabetologie und Stoffwechsel, 19(S 01 S 01), S73. https://doi.org/10.1055/s-0044-1785380

Vancouver

Knop FK, Urva S, Rettiganti M, Benson CT, Roell WC, Mather KJ, et al. A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy. Diabetologie und Stoffwechsel. 2024;19(S 01 S 01):S73. doi:10.1055/s-0044-1785380

BibTeX
@article{Knop2024,
  author = {Knop, Filip K. and Urva, Shweta and Rettiganti, Mallikarjuna and Benson, Charles T. and Roell, William C. and Mather, Kieren J. and Haupt, Axel and Pratt, Edward and Füchtenbusch, Martin},
  title = {A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy},
  journal = {Diabetologie und Stoffwechsel},
  year = {2024},
  volume = {19},
  number = {S 01 S 01},
  pages = {S73},
  doi = {10.1055/s-0044-1785380}
}
Kostenlos starten →